Brief: Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas
20/01/2026 13:03
Jan 20 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SOFT TISSUE SARCOMAS Source text: ID:nBw858hTTa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview